NC
SUPN icon

NewSquare Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

NewSquare Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-117
Closed -$3K – 437
2016
Q3 		$3K Buy
+117
New +$2.65K ﹤0.01% 410

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NewSquare Capital's SUPN Position: Q4 2016 in Review

NewSquare Capital sold out of Supernus Pharmaceuticals (SUPN) in Q4 2016, closing a stake of 117 shares — an estimated $3K sold.

NewSquare Capital first reported a position in SUPN in Q3 2016 and held it in 1 quarter. The position peaked at $3K in Q3 2016. 233 funds tracked by Wall St. Rank hold SUPN as of Q4 2016.

  • NewSquare Capital reported no remaining Supernus Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • NewSquare Capital sold 117 Supernus Pharmaceuticals shares in Q4 2016, an estimated $3K.
  • NewSquare Capital first reported a position in Supernus Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • NewSquare Capital's Supernus Pharmaceuticals position peaked at $3K in Q3 2016.
  • 233 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2016.

Based on NewSquare Capital's 13F filing for Q4 2016, filed 1 Feb 2017.